Peregrine Pharmaceuticals (NASDAQ: CDMO) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Peregrine Pharmaceuticals to similar businesses based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, earnings and profitability.

Insider & Institutional Ownership

18.7% of Peregrine Pharmaceuticals shares are held by institutional investors. Comparatively, 42.7% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 2.5% of Peregrine Pharmaceuticals shares are held by insiders. Comparatively, 15.3% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


This table compares Peregrine Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Peregrine Pharmaceuticals -39.23% -52.55% -24.77%
Peregrine Pharmaceuticals Competitors -13,486.88% -54.11% -24.57%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Peregrine Pharmaceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Peregrine Pharmaceuticals 0 0 1 0 3.00
Peregrine Pharmaceuticals Competitors 158 826 1813 61 2.62

Peregrine Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 174.73%. As a group, “Biopharmaceuticals” companies have a potential upside of 1.60%. Given Peregrine Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Peregrine Pharmaceuticals is more favorable than its rivals.

Earnings and Valuation

This table compares Peregrine Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Peregrine Pharmaceuticals $57.63 million -$28.15 million -4.49
Peregrine Pharmaceuticals Competitors $584.27 million $101.79 million 80.83

Peregrine Pharmaceuticals’ rivals have higher revenue and earnings than Peregrine Pharmaceuticals. Peregrine Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Peregrine Pharmaceuticals has a beta of 2.74, indicating that its stock price is 174% more volatile than the S&P 500. Comparatively, Peregrine Pharmaceuticals’ rivals have a beta of 1.04, indicating that their average stock price is 4% more volatile than the S&P 500.


Peregrine Pharmaceuticals rivals beat Peregrine Pharmaceuticals on 7 of the 13 factors compared.

About Peregrine Pharmaceuticals

Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., incorporated on September 25, 1996, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.

Receive News & Ratings for Peregrine Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals and related companies with's FREE daily email newsletter.